Development of gene expression-based risk score in cytogenetically normal acute myeloid leukemia patients

Oncotarget

Volumn 3, Issue 8, 2012, Pages 824-832

  Samra, Elias Bou ^a,b   Klein, Bernard ^a,b,c   Commes, Thérèse ^a,b   Moreaux, Jérôme ^a,b  

^a UNIV MONTPELLIER   (France)

^b INSERM   (France)

^c MONTPELLIER UNIVERSITY HOSPITAL   (France)

Author keywords

Cytogenetically normal acute myeloid leukemia; EVI1 expression; Gene expression based risk score; Prognostic gene signature

Indexed keywords

TRANSCRIPTION FACTOR ERG;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; BAALC GENE; CANCER PROGNOSIS; CANCER RISK; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; ERG GENE; EVI1 GENE; GENE; GENE EXPRESSION; GENE EXPRESSION BASED RISK SCORE; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MN1 GENE; NUCLEOTIDE SEQUENCE; OVERALL SURVIVAL; RISK ASSESSMENT; SURVIVAL TIME;

EID: 84868624757     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.571     Document Type: Article

References (37)

1. Mrózek K, Heerema NA, Bloomfield CD. Cytogenetics in acute leukemia. Blood Reviews. 2004; 18:115-136
2. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, Rees J, Hann I, Stevens R, Burnett A, Goldstone A. The Importance of Diagnostic Cytogenetics on Outcome in AML: Analysis of 1,612 Patients Entered Into the MRC AML 10 Trial. Blood. 1998; 92:2322-2333
3. Mrózek K, Marcucci G, Paschka P, Whitman SP, Bloomfield CD. Clinical Relevance of Mutations and Gene- Expression Changes in Adult Acute Myeloid Leukemia with Normal Cytogenetics: Are We Ready for a Prognostically Prioritized Molecular Classification? Blood. 2007; 109:431- 448
4. Haferlach C, Kern W, Schindela S, Kohlmann A, Alpermann T, Schnittger S, Haferlach T. Gene expression of BAALC, CDKN1B, ERG, and MN1 adds independent prognostic information to cytogenetics and molecular mutations in adult acute myeloid leukemia. Genes Chromosomes Cancer. 2012; 51:257-265
5. Döhner K, Schlenk RF, Habdank M, Scholl C, Rücker FG, Corbacioglu A, Bullinger L, Fröhling S, Döhner H. Mutant Nucleophosmin (NPM1) Predicts Favorable Prognosis in Younger Adults with Acute Myeloid Leukemia and Normal Cytogenetics: Interaction with Other Gene Mutations. Blood. 2005; 106:3740-3746
6. Bullinger L, Dohner K, Bair E, Frohling S, Schlenk RF, Tibshirani R, Dohner H, Pollack JR. Use of Gene- Expression Profiling to Identify Prognostic Subclasses in Adult Acute Myeloid Leukemia. The New England Journal of Medecine. 2004; 350:1605-1616
7. Radmacher MD, Marcucci G, Ruppert AS, Mrózek K, Whitman SP, Vardiman JW, Paschka P, Vukosavljevic T, Baldus CD, Kolitz JE, Caligiuri MA, Larson RA, Bloomfield CD. Independent Confirmation of a Prognostic Gene-Expression Signature in Adult Acute Myeloid Leukemia with a Normal Karyotype: A Cancer and Leukemia Group B Study. Blood. 2006; 108:1677-1683
8. Metzeler KH et al. An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia. Blood. 2008; 112:4193-4201
9. Moreaux J, Klein B, Bataille R, Descamps G, Maïga S, Hose D, Goldschmidt H, Jauch A, Rème T, Jourdan M, Amiot M, Pellat-Deceunynck C. A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines. Haematologica. 2011; 96:574-582
10. Kassambara A, Hose D, Moreaux J, Walker BA, Protopopov A, Reme T, Pellestor F, Pantesco V, Jauch A, Morgan G, Goldschmidt H, Klein B. Genes with a spike expression are clustered in chromosome (sub)bands and spike (sub)bands have a powerful prognostic value in patients with multiple myeloma. Haematologica. 2011; DOI: 10.3324/haematol.2011.046821
11. Wouters BJ, Löwenberg B, Delwel R. A decade of genome-wide gene expression profiling in acute myeloid leukemia: flashback and prospects. Blood. 2009; 113:291 -298
12. Bou Samra E, Moreaux J, Vacheret F, Mills K, Rufflé F, Chiesa J, Piquemal D, Boureux A, Lavabre-Bertrand T, Jourdan E, Commes T. New prognostic markers, determined using gene expression analyses, reveal two distinct subtypes of chronic myelomonocytic leukaemia patients. British Journal of Haematology. 2012; 157:347- 356
13. Pise-Masison CA, Radonovich M, Dohoney K, Morris JC, O'Mahony D, Lee M-J, Trepel J, Waldmann TA, Janik JE, Brady JN. Gene Expression Profiling of ATL Patients: Compilation of Disease-Related Genes and Evidence for TCF4 Involvement in BIRC5 Gene Expression and Cell Viability. Blood. 2009; 113:4016-4026
14. Lugthart S, Cheok MH, den Boer ML, Yang W, Holleman A, Cheng C, Pui C-H, Relling MV, Janka-Schaub GE, Pieters R, Evans WE. Identification of genes associated with chemotherapy crossresistance and treatment response in childhood acute lymphoblastic leukemia. Cancer Cell. 2005; 7:375-386
15. Gandillet A, Park S, Lassailly F, Griessinger E, Vargaftig J, Filby A, Lister TA, Bonnet D. Heterogeneous sensitivity of human acute myeloid leukemia to β-catenin down-modulation. Leukemia. 2011; 25:770-780
16. Tian W, Han X, Yan M, Xu Y, Duggineni S, Lin N, Luo G, Li YM, Han X, Huang Z, An J. Structure-Based Discovery of a Novel Inhibitor Targeting the β-Catenin/ Tcf4 Interaction. Biochemistry. 2011; 51:724-731
17. Byers RJ, Currie T, Tholouli E, Rodig SJ, Kutok JL. MSI2 Protein Expression Predicts Unfavorable Outcome in Acute Myeloid Leukemia. Blood. 2011; 118:2857-2867
18. Zheng C, Li L, Haak M, Brors B, Frank O, Giehl M, Fabarius A, Schatz M, Weisser A, Lorentz C, Gretz N, Hehlmann R, Hochhaus A, Seifarth W. Gene expression profiling of CD34+ cells identifies a molecular signature of chronic myeloid leukemia blast crisis. Leukemia. 2006; 20:1028-1034
19. Haferlach T et al. Clinical Utility of Microarray-Based Gene Expression Profiling in the Diagnosis and Subclassification of Leukemia: Report From the International Microarray Innovations in Leukemia Study Group. Journal of Clinical Oncology. 2010; 28:2529 -2537
20. de Andres-Aguayo L, Varas F, Graf T. Musashi 2 in hematopoiesis. [Miscellaneous Article]. Current Opinion in Hematology July 2012. 2012; 19:268-272
21. Kharas MG et al. Musashi-2 regulates normal hematopoiesis and promotes aggressive myeloid leukemia. Nature Medicine. 2010; 16:903-908
22. Ito T et al. Regulation of myeloid leukaemia by the cell-fate determinant Musashi. Nature. 2010; 466:765-768
23. Allioli N, Vincent S, Vlaeminck-Guillem V, Decaussin- Petrucci M, Ragage F, Ruffion A, Samarut J. TM4SF1, a novel primary androgen receptor target gene over-expressed in human prostate cancer and involved in cell migration. The Prostate. 2011; 71:1239-1250
24. Diss JKJ, Stewart D, Pani F, Foster CS, Walker MM, Patel A, Djamgoz MBA. A potential novel marker for human prostate cancer: voltage-gated sodium channel expression in vivo. Prostate Cancer and Prostatic Diseases. 2005; 8:266- 273
25. Gordon GJ, Bueno R, Sugarbaker DJ. Genes associated with prognosis after surgery for malignant pleural mesothelioma promote tumor cell survival in vitro. BMC Cancer. 2011; 11:169
26. Shih S-C, Zukauskas A, Li D, Liu G, Ang L-H, Nagy JA, Brown LF, Dvorak HF. The L6 Protein TM4SF1 Is Critical for Endothelial Cell Function and Tumor Angiogenesis. Cancer Res. 2009; 69:3272-3277
27. Maicas M, Vázquez I, Vicente C, García-Sánchez MA, Marcotegui N, Urquiza L, Calasanz MJ, Odero MD. Functional characterization of the promoter region of the human EVI1 gene in acute myeloid leukemia: RUNX1 and ELK1 directly regulate its transcription. Oncogene. 2012;
28. Wieser R. The oncogene and developmental regulator EVI1: Expression, biochemical properties, and biological functions. Gene. 2007; 396:346-357
29. Laricchia-Robbio L, Fazzina R, Li D, Rinaldi CR, Sinha KK, Chakraborty S, Nucifora G. Point Mutations in Two EVI1 Zn Fingers Abolish EVI1-GATA1 Interaction and Allow Erythroid Differentiation of Murine Bone Marrow Cells. Mol. Cell. Biol. 2006; 26:7658-7666
30. Laricchia-Robbio L, Premanand K, Rinaldi CR, Nucifora G. EVI1 Impairs Myelopoiesis by Deregulation of PU.1 Function. Cancer Res. 2009; 69:1633-1642
31. Senyuk V, Sinha KK, Li D, Rinaldi CR, Yanamandra S, Nucifora G. Repression of RUNX1 Activity by EVI1: A New Role of EVI1 in Leukemogenesis. Cancer Res. 2007; 67:5658-5666
32. Langabeer SE, Rogers JR, Harrison G, Wheatley K, Walker H, Bain BJ, Burnett AK, Goldstone AH, Linch DC, Grimwade D, Party OBOTMALW. EVI1 expression in acute myeloid leukaemia. British Journal of Haematology. 2001; 112:208-211
33. Lugthart S, Van Drunen E, Van Norden Y, Van Hoven A, Erpelinck CAJ, Valk PJM, Beverloo HB, Löwenberg B, Delwel R. High EVI1 Levels Predict Adverse Outcome in Acute Myeloid Leukemia: Prevalence of EVI1 Overexpression and Chromosome 3q26 Abnormalities Underestimated. Blood. 2008; 111:4329-4337
34. Cui X, Churchill GA. Statistical tests for differential expression in cDNA microarray experiments. Genome Biol. 2003; 4:210-210
35. R Development Core Team. R: A language and environment for statistical computing, 3-900051-07-0R Foundation for Statistical Computing, Vienna, Austria. 2010;
36. Gentleman RC et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 2004; 5:R80
37. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A. 1998; 95:14863-14868